[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611629":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":37,"centralContacts":41,"locations":47,"responsibleParty":63,"collaborators":10,"id":65,"slug":10,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":10,"eligibilityCriteria":69,"healthyVolunteers":66,"sex":70,"minAge":10,"maxAge":10,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":10,"overallStatus":82,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,15,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Clear-cell RCC",null,"Participants with clear-cell RCC",[13,14],"Other: Proteomic profiling of urinary EVs","Procedure: Blood sample collection",{"label":16,"type":10,"description":17,"interventionNames":18},"Papillary RCC","Participants with papillary RCC",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Chromophobe RCC","Participants with chromophobe RCC",[13,14],{"label":24,"type":10,"description":25,"interventionNames":26},"Benign Renal Tumor","Participants with benign renal tumors",[13],[28,32],{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":10},"Proteomic profiling of urinary EVs","EV isolation and mass spectrometry.",[24,20,9,16],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":10},"PROCEDURE","Blood sample collection","Blood samples collected pre- and post-nephrectomy",[20,9,16],[38],{"name":39,"affiliation":5,"role":40},"Fabrice Lucien-Matteoni, MD","PRINCIPAL_INVESTIGATOR",[42],{"name":43,"role":44,"phone":45,"phoneExt":10,"email":46},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",[48],{"facility":49,"status":10,"city":50,"state":51,"zip":52,"country":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Mayo Clinic in Rochester","Rochester","Minnesota","55905","United States",{"type":55,"coordinates":56},"Point",[57,58],-92.4699,44.02163,{"lat":58,"lon":57},[61,62],{"name":43,"role":44,"phone":45,"phoneExt":10,"email":46},{"name":39,"role":40,"phone":10,"phoneExt":10,"email":10},{"type":64,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100611629",false,"NCT07243067","Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer","Inclusion Criteria:\n\n* Urine sample in existing biorepository\n* High-risk renal cell carcinoma (RCC) per American Urological Association (AUA) guidelines\n* Scheduled to undergo nephrectomy\n\nExclusion Criteria:\n\n* Does not meet inclusion criteria","ALL",{"count":72,"type":73},300,"ESTIMATED","OBSERVATIONAL","This is a correlative (lab-based) study aiming to identify protein markers in urine extracellular vesicles (EVs) that can be used to develop non-invasive molecular tests for patients with renal cell carcinoma (RCC). Aim 1 will use urine collected previously in biorepository. Aim 2 will prospectively collect blood specimens pre and post nephrectomy.",[77,78,79,80,81],"Renal Cell Carcinoma","Clear-cell Renal Cell Carcinoma","Papillary Renal Cell Carcinoma","Chromophobe Renal Cell Carcinoma","Kidney Cancer","NOT_YET_RECRUITING","2026-02-24",{"date":85,"type":86},"2026-02-27","ACTUAL",{"date":88,"type":73},"2026-07-15",{"date":90,"type":73},"2027-04-30",{"name":5,"class":6},1]